# US 2013/0156799 A1 · Contiguous overlapping peptides for treatment of birch pollen allergy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156799 A1 - Document ID: US20130156799A1 - Status: Published application - Kind: A1 - Application number: 13/718,264 - Filed: 2012-12-18 - Published: 2013-06-20 - Earliest claimed: 2009-02-09 - Assignees: Anergis S.A. - Inventors: Christophe Reymond; Francois Spertini - Web page: https://patentgrep.com/patent/US20130156799A1 ## CPC - A61K 39/36: from pollen - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - C07K 14/415: from plants - A61K 2039/55505: {Inorganic adjuvants} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of birch pollen Bet v 1. Such peptides while providing all potential T cell epitopes are devoid of the 3D structure of the original allergen, therefore reducing their ability to bind IgE. ## Claims ### Claim 1 A composition comprising a plurality of contiguous overlapping peptide fragments comprising a first peptide having 90% sequence identity with the peptide consisting of the sequence from amino acid 2 to amino acids 42-52 of SEQ ID NO: 9 wherein the reactivity of said first peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained; a second polypeptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 42-52 to amino acids 96-131 of SEQ ID NO: 9 wherein the reactivity of said second peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained and a third peptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 96-131 to amino acid 160 of SEQ ID NO: 9 wherein the reactivity of said third peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained. ### Claim 2 (depends on 1) The composition of claim 1 wherein the first and second peptides overlap each other by 1 to 11 amino acids. ### Claim 3 (depends on 1) The composition of claim 1 wherein the second and third peptides overlap each other by 5 to 20 amino acids. ### Claim 4 A peptide having 90% sequence identity with the peptide consisting of the sequence from amino acid 2 to amino acids 42-52 of SEQ ID NO: 9 wherein the reactivity of said peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained. ### Claim 5 A peptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 42-52 to amino acids 96-131 of SEQ ID NO: 9 wherein the reactivity of said peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained. ### Claim 6 A peptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 96-131 to amino acid 160 of SEQ ID NO: 9 wherein the reactivity of said peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained. ### Claim 7 (depends on 4, 5, 6) The composition of anyone of claim 4, 5 or 6 which is provided in dry powdered form. ### Claim 8 (depends on 4, 5, 6) The composition of anyone of claim 4, 5 or 6 further comprising a pharmaceutically acceptable carrier or diluent. ### Claim 9 (depends on 8) The composition of claim 8 further comprising an adjuvant. ### Claim 10 (depends on 9) The composition of claim 9 wherein the adjuvant is aluminium hydroxide. ### Claim 11 A method of specific immunotherapy against birch pollen allergies comprising administering to a patient in need thereof one or more allergens selected from the group consisting of a first peptide having 90% sequence identity with the peptide consisting of the sequence from amino acid 2 to amino acids 42-52 of SEQ ID NO: 9 wherein the reactivity of said first peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained; a second polypeptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 42-52 to amino acids 96-131 of SEQ ID NO: 9 wherein the reactivity of said second peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained and a third peptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 96-131 to amino acid 160 of SEQ ID NO: 9 wherein the reactivity of said third peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained. ### Claim 12 (depends on 11) The method of claim 11 wherein the peptides are administered using intradermal injection, subcutaneous injection, intramuscular injection, intravenous injection, transdermal, intranasal, oral, sublingual, intraocular, or intrathecal techniques. ### Claim 13 (depends on 11) The method of claim 11 wherein the patient is treated with the combination of each of a first peptide having 90% sequence identity with the peptide consisting of the sequence from amino acid 2 to amino acids 42-52 of SEQ ID NO: 9 wherein the reactivity of said first peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained; a second peptide having 90% sequence identity with the peptide consisting of the sequence from amino acids 42-52 to amino acids 96-131 of SEQ ID NO: 9 wherein the reactivity of said second peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained and a third peptide consisting of the sequence from amino acids 96-131 to amino acid 160 of SEQ ID NO: 9 wherein the reactivity of said third peptide having 90% sequence identity with the peptide to IgE antibodies of subjects who are allergic to birch pollen is eliminated while the reactivity with the T lymphocytes from subjects who are allergic to birch pollen is retained. ### Claim 14 (depends on 11) The method of claim 11 wherein the first and second peptides overlap each other by at least 1 to 11 amino acids. ### Claim 15 (depends on 11) The method of claim 11 wherein the second and third peptides overlap each other by at least 5-20 amino acids.